G2B Pharma Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

G2B Pharma General Information

Description

Developer of a needle-free alternative for epinephrine using the nasal delivery route. The company's product is a nasal spray formulation of epinephrine for the treatment of anaphylaxis, providing patients with an effective and more patient-friendly delivery route for this life-saving medication.

Contact Information

Website
www.g2bpharma.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 5 Presidio Court
  • Corte Madera, CA 94925
  • United States
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Acquirer
StellaPharma (North Carolina)
Corporate Office
  • 5 Presidio Court
  • Corte Madera, CA 94925
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

G2B Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore G2B Pharma‘s full profile, request access.

Request a free trial

G2B Pharma Patents

  • 10

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

G2B Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2014315459-A1 Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions Inactive 03-Sep-2013
CA-2923270-A1 Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions Inactive 03-Sep-2013
EP-3041461-A1 Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions Inactive 03-Sep-2013
US-20160220489-A1 Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions Inactive 03-Sep-2013
EP-3041461-A4 Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions Inactive 03-Sep-2013 A61K9/14
To view G2B Pharma’s complete patent history, request access »

G2B Pharma FAQs

  • When was G2B Pharma founded?

    G2B Pharma was founded in 2008.

  • Where is G2B Pharma headquartered?

    G2B Pharma is headquartered in Corte Madera, CA.

  • What industry is G2B Pharma in?

    G2B Pharma’s primary industry is Drug Delivery.

  • Is G2B Pharma a private or public company?

    G2B Pharma is a Private company.

  • What is G2B Pharma’s current revenue?

    The current revenue for G2B Pharma is .

  • How much funding has G2B Pharma raised over time?

    G2B Pharma has raised $235K.

  • When was G2B Pharma acquired?

    G2B Pharma was acquired on 15-Jan-2019.

  • Who acquired G2B Pharma?

    G2B Pharma was acquired by StellaPharma (North Carolina).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »